Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.

Therapeutic vaccination of tumor patients with cytokine gene-transfected tumor cells leads to tumor regression in animal models but has so far not resulted in significant clinical benefit. We and others demonstrated that tumor cells transfected to mediate overexpression of a cytokine gene activate immunologic effector cells for an improved proliferation rate and significantly higher antitumoral cytotoxic activity. Here, we performed a pilot study of therapeutic vaccination in patients with metastatic disease. Autologous tumor cells were simultaneously transfected with novel minimalistic, immunogenically defined, gene expression constructs (MIDGE) for overexpression of the two cytokines interleukin 7 (IL-7) and GM-CSF and newly designed double stem-loop immunomodulating oligodeoxyribonucleotides (d-SLIM) as a Th1-promoting and NK cell-stimulating adjuvant. Transfection was performed ex vivo by ballistomagnetic gene transfer. Patients received four subcutaneous injections of at least 1 x 10(6) of their expression-modulated and immunomodified autologous tumor cells. Ten patients have been enrolled in the study protocol. In all patients no adverse effects could be detected. IL-7 and interferon gamma levels were elevated in the serum of the patients after treatment. Interestingly, cytotoxicity of patient-derived PBLs increased significantly during treatment. All 10 patients had progressive disease when entering our protocol. One complete, one partial, and one mixed response with progression of abdominal metastases and regression of lung metastases were observed. Two patients showed a stable disease after treatment and five patients remained in progressive disease. Our observations confirm the capability of autologous expression-modified and immunomodulated tumor cell vaccines to stimulate a strong immune response in patients with metastatic cancer even in the presence of a large tumor burden.

[1]  S. Plaeger,et al.  Cytokines as adjuvants for HIV DNA vaccines , 2002 .

[2]  A. Gambotto,et al.  Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  I. Schmidt-Wolf,et al.  Immunomodulatory gene therapy for haematological malignancies , 2002, British journal of haematology.

[4]  W. Hinterberger,et al.  Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy , 2001, Expert opinion on biological therapy.

[5]  F. Paillard.  The search for the "best" cytokine to induce antitumor immunity. , 1998, Human gene therapy.

[6]  A. Krieg,et al.  CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. , 1998, Journal of immunology.

[7]  D. Schadendorf,et al.  Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study , 1998, Gene Therapy.

[8]  D. Pisetsky.  Immunostimulatory DNA: A clear and present danger , 1997, Nature Medicine.

[9]  D. Richman,et al.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.

[10]  D. Schadendorf,et al.  Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. , 1997, Cancer gene therapy.

[11]  E. Raz,et al.  Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization , 1996, Science.

[12]  D. Huhn,et al.  Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. , 1994, Human gene therapy.

[13]  D. Schadendorf,et al.  Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. , 1994, The Journal of investigative dermatology.

[14]  R. Foà,et al.  Cytokine gene therapy: a new strategy for the management of cancer patients. , 1994, Natural immunity.

[15]  M. Walker,et al.  Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. , 1993, Blood.

[16]  D. Longo,et al.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. , 1993, The Journal of clinical investigation.

[17]  T. Blankenstein,et al.  Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. , 1993, Cancer research.

[18]  E. Gilboa,et al.  A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. , 1992, Human gene therapy.

[19]  W. McBride,et al.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.

[20]  S. Rosenberg,et al.  Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy , 1991, The Journal of experimental medicine.

[21]  I. Schmidt-Wolf,et al.  Lymphokine-activated killer cell activity after cryopreservation. , 1989, Journal of immunological methods.

[22]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[23]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.